drugset / Trial / NCT04675944

Effect of BIA 5-1058 on the Steady State Pharmacokinetics of Treprostinil

NCT04675944

Phase 1 Completed 20 enrolled Bial - Portela C S.A.
NaSequentialOpen-labelTreatment

Summary

The purpose of this study is to assess the effect of BIA 5-1058 200 mg on the pharmacokinetic (PK) of treprostinil

Timeline

Start
2018-02-28
Primary completion
2018-05-25
Completion
2018-05-25

Drugs

EvaluationDrugModalityDoseRoute
Subject Treprostinil Other / unclassified 1 mg Oral
Subject zamicastat Small molecule 200 mg Oral